HOME >> MEDICINE >> NEWS
Second NIAID SARS vaccine candidate helps mice fend off SARS

An experimental vaccine based on a critical piece of the SARS virus protects mice from SARS infection, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have found. When exposed to the SARS virus, immunized mice produced SARS-specific antibodies, and virus replication was nearly eliminated.

The new report, to be published this week in the Proceedings of the National Academy of Sciences online, is the second from NIAID in recent weeks describing a promising SARS vaccine candidate.

"We now have two candidate vaccines, based on two distinct technologies, shown to be effective against SARS infection in mice," says NIAID Director Anthony S. Fauci, M.D. "The animal model employed in both studies was developed by NIAID researchers as well. By taking various approaches to vaccine development, we are making significant research progress against a disease that was unknown little more than a year ago."

SARS is caused by a coronavirus, a family of viruses so named because spiky proteins protrude from the virus's surface, giving the microbe a crown-like appearance. The newly described vaccine is based on the spike (S) protein. Because the virus initiates infection by attaching to and entering cells using its S protein, a vaccine based on this protein should closely mimic natural infection, notes senior author, Bernard Moss, M.D., Ph.D.

Investigators inserted the gene encoding the S protein into a virus called modified vaccinia Ankara (MVA). Neither MVA nor the solitary gene from the SARS virus can cause disease. Instead, MVA simply ferries the SARS gene into the body. First developed as a vaccine against smallpox, MVA has an excellent safety record in humans, says Dr. Moss, and it efficiently stimulates both the antibody and cellular arms of the immune system.

Dr. Moss and his colleagues collaborated in this research with fellow NIAID scientist Kanta Subbarao,
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
19-Apr-2004


Page: 1 2

Related medicine news :

1. Secondhand smoke linked to cervical cancer
2. Secondhand smoke impairs lung function in women
3. Second stage of HIV vaccine trial begins in London and Oxford, UK
4. Second patient with multiple sclerosis undergoes groundbreaking surgery at Yale
5. Cholesterol Carriers Better Predictors Than Cholesterol For Second Heart Attack
6. Second Annual AIDS Vaccine Day Honors Volunteers Nationwide
7. Patients Treated Successfully For Hodgkins Disease Are At 9 Times The Risk For Developing Second Cancer
8. Cedars-Sinai Medical Centers Prenatal Program Pushes the Frontiers of Diagnosis From the Second Trimester Into the First
9. AAPS Sponsors Second Frontier Symposium
10. Drug Combination Including New "Super Aspirin" Drug Cuts Risk Of Death Or Second Heart Attack
11. Drugs Effect On Chromosomes May Explain Second Cancers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Second NIAID SARS vaccine candidate helps mice fend off SARS

(Date:7/30/2014)... Neil Haley, the Total Tutor host of ... to find out about what is branding, how am I ... , Reynolds is an original founding member of the company ... and CEO of Simply G Media. He has written a ... holds the distinction of completing the Dale Brown and Project ...
(Date:7/30/2014)... Pain Free Living web: Superior Magnetics ... relief and improved performance. This new magnetic sports bracelet ... silicone core that is sheathed in nylon soaked in ... with scalar energy and Schumann frequency thus making it ... 12 years experience developing magnetic bracelets. We developed the ...
(Date:7/29/2014)... Paul Mata, CEO of ‘Create Indestructible Wealth,’ ... 30 Days” E-book. The e-book includes a myriad of fast ... cash. Examples include downloading and utilizing specific phone apps ... people monetize the assets they didn't know they had like ... find in their garage. , After reading the e-book, ...
(Date:7/29/2014)... 1Heart Caregiver Services’ advocacy on ... on Brain Fitness Education brings great acceptance from ... Program Director Tee Barr delivered an exceptional Brain ... and the Assisted Living section of Aegis Ventura ... Christy Rozsa and Aegis Life Neighborhood Director Christine ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip indicates ... as all other disturbing symptoms that hemorrhoids commonly causes. ... researcher and natural medicine expert. , The author ... to the elimination of symptoms such as itching, burning, ... Learn more about the H Miracle by visiting the ...
Breaking Medicine News(10 mins):Health News:Entrepreneur and Vi Millioniare GJ Reynolds Discusses How to Improve Your Brand on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:H Miracle Review Exposes Natural Method to Cure Hemorrhoids 2
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
(Date:7/29/2014)... Israel , July 30, 2014  Immune ... Stockholm : "IMNP."; "Immune" or "the ... of patients for a Phase II proof of concept ... in the treatment of moderate to severe bullous pemphigoid. ... receive two bertilimumab infusions, at a dose of 10 ...
Breaking Medicine Technology:Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5
Cached News: